Intangible Assets, net (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended					3 Months Ended
	Mar. 31, 2014 product	Mar. 31, 2013	Mar. 31, 2014 Sky Growth Merger [Member] Developed products [Member]	Mar. 31, 2014 Sky Growth Merger [Member] Subsequently Developed In Process Research and Development [Member]	Nov. 06, 2012 Watson/Actavis Divestiture Products [Member] product drug_application	Mar. 31, 2014 Watson/Actavis Divestiture Products [Member]	Mar. 31, 2014 JHP Group Holdings [Member] annual_IPRD_group	Mar. 31, 2014 JHP Group Holdings [Member] Developed products [Member]	Mar. 31, 2014 JHP Group Holdings [Member] Trade Names [Member]
Intangible Assets, Net (Excluding Goodwill) [Line Items]
Amortization expense related to intangible assets	$ 44,102	$ 40,071
Weighted average amortization period			6 years	7 years		6 years		10 years	5 years
Number of generic products with marketing rights acquired through merger (products)					5
Number of abbreviated new drug applications awaiting regulatory approval (products)					8
Number of IPR&D groups created							6
Intangible asset impairment	$ 41,758	$ 0
Number of products impaired not expected to achieve forecasted operating results	2